Increasing Biologics Use May Demand New Safety Surveillance Outlook, Expert Says

Drug Industry Daily
A A
The FDA and drugmakers need to revamp pharmacovigilance efforts for biologics as their use increases because they present different risks than small-molecule drugs, one expert says.

To View This Article:

Login

Subscribe To Drug Industry Daily